The Global Antibody-mediated Rejection Market is driven by increasing organ transplantation procedures

Antibody-mediated Rejection or AMR occurs when a transplant recipient's immune system produces antibodies against donor tissue, leading to transplant rejection. These antibodies can be preformed, existing prior to transplantation, or de novo antibodies produced after transplantation. AMR affects mainly heart, kidney and lung allografts, compromising transplant success and long-term outcomes.

To prevent and treat AMR, immunosuppressive regimens that include drugs such as intravenous immunoglobulin, plasmapheresis, rituximab, bortezomib and complement inhibitors are commonly used. The global antibody-mediated rejection market comprises such therapies that aid in managing AMR by eliminating preformed and de novo donor-specific antibodies. According to sources
The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.

Antibody-mediated Rejection Market -https://www.coherentmi.com/ind....ustry-reports/antibo